WS #17016
M&A activity continues with Bernhard Capital Partners completing a $1 billion acquisition of Bowman Consulting Group. In the healthcare sector, Acrivon Therapeutics expanded its pipeline with the acquisition of a Phase 2 JAK1 inhibitor. These deals reflect ongoing consolidation in professional services and targeted expansion in biotech, though they are secondary to the macro-driven market volatility.
Corporate M&A and Spin-offs
M&A activity continues with Bernhard Capital Partners completing a $1 billion acquisition of Bowman Consulting Group. In the healthcare sector, Acrivon Therapeutics expanded its pipeline with the acquisition of a Phase 2 JAK1 inhibitor. These deals reflect ongoing consolidation in professional services and targeted expansion in biotech, though they are secondary to the macro-driven market volatility.